Journal of Alzheimer s Disease · 2018 · 30 citations · 10 references
PharmacyData SciencePharmacoeconomicsDementiaEvidence-based PracticePharmacoeconomic ModelingAlzheimer DiseaseClinical TrialsEvidence-based MedicineModel-based Economic EvaluationReal-world EvidenceReal-world Evidence In RepurposingData Synthesis From Multiple SourcesPatient Outcomes MeasurementPharmacoeconomic SimulationPublic-private Partnership DevelopmentPublic-private Partnership EvaluationReal-world Evidence AppraisalReal-world Evidence EvaluationReal-world Evidence Modeling
ROADMAP is a public-private advisory partnership to evaluate the usability of multiple data sources, including real-world evidence, in the decision-making process for new treatments in Alzheimer's disease, and to advance key concepts in disease and pharmacoeconomic modeling. ROADMAP identified key disease and patient outcomes for stakeholders to make informed funding and treatment decisions, provided advice on data integration methods and standards, and developed conceptual cost-effectiveness and disease models designed in part to assess whether early treatment provides long-term benefit.
10
Real-World Evidence — What Is It and What Can It Tell Us?
Rachel E. Sherman, Steven A. Anderson, Gerald J. Dal Pan et al. · New England Journal of Medicine · 2016 · 2.1K citations